Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UX007 for Movement Disorders in Glut1 DS
NCT02960217Phase 3Terminated
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Apr 2017
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of triheptanoin in Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS) (2 arms), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoints: Maintenance Phase Movement Disorder Frequency, Number of Participants With Treatment Emergent Adverse Events and 1 more. Started Apr 2017; status: terminated.
02
Drugs
triheptanoin
03
Conditions
Glucose Transporter Type 1 Deficiency Syndrome (Glut1DS)
Beyond the preview
Go deeper on NCT02960217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960217.